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SUMMARY
Schistosomiasis haematobia or urinary schistosomiasis is one of the main public health problems in Africa and the Middle East. 
A single dose of 40 mg praziquantel per kg body weight continues to be the treatment of choice for this infection. The aims of this 
follow-up were to study the post-treatment course of a patient infected with S. haematobium and not submitted to re-exposure, and to 
identify complications of the disease and/or therapeutic failure after praziquantel treatment by histopathological analysis. Treatments 
were repeated under medical supervision to ensure the correct use of the drug. In view of the suspicion of lesions in cystoscopy, the 
patient was submitted to bladder biopsy. The histopathological characteristics observed in biopsies obtained, after each treatment, 
indicated viability of parasite eggs and activity of granulomas. 
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INTRODUCTION
Schistosomiasis haematobia or urinary schistosomiasis is one of the 
main public health problems in Africa and the Middle East. A single dose 
of 40 mg praziquantel per kg body weight continues to be the treatment of 
choice for this infection. However, cases of treatment failure with a single 
dose of praziquantel have been reported in the literature and divergences 
exist regarding the speed and magnitude of this event2,4. There are also 
reports indicating that early treatment with praziquantel is less effective 
in the prevention of acute schistosomiasis than treatment during later 
phases, with early treatment failing to prevent the progression to chronic 
schistosomiasis in all cases studied3.
Although praziquantel is the first-line drug for the treatment of 
infection with Schistosoma haematobium, efficacy monitoring is 
recommended because of the possible development of resistance, 
especially in the case of mass treatment. One study has even reported 
therapeutic failure with two or three doses of 40 mg/kg praziquantel, 
despite the high rate of cure (93%) and a 96.6% reduction in the number 
of eggs in 354 schoolchildren aged 5-15 years. It was reported that 20 
schoolchildren remained egg-positive after the second treatment and 80% 
(16/20) became egg-negative after the third treatment5. 
In the absence of therapeutic failure, treatment with praziquantel 
results in the complete reduction of the cellular reaction and fibrosis in 
tissues containing a known number of dead residual eggs1. 
The follow-up of treated patients is important for the identification 
of cases of therapeutic failure. These cases can be well documented 
among patients who do not return to endemic areas, and therefore are 
not submitted to re-exposure. 
MATERIALS AND METHODS
A patient had been infected with the parasite in 1994 during a UN 
peace mission, when he bathed in the Licungo River, Mozambique, Africa. 
The patient noted hematuria in 1997, about three years after exposure, 
when he had already returned to Brazil. In 2000, after notification to the 
Army Biology Institute, the patient paid more attention to these sporadic 
episodes of urinary bleeding. After clinical investigation of the patient 
who reported episodes of macroscopic hematuria, who was negative 
for bacteria in urine (abnormal elements and sedimentoscopy and urine 
culture) and who presented no urinary lithiasis, a 24-h urine sample was 
obtained and submitted to parasitological analysis. 
For parasitological examination, a 24-h urine sample was collected, 
followed by spontaneous sedimentation for 24 h. Ten milliliter of the sediment 
was then removed and centrifuged at 5000 rpm and a 10-µL aliquot was 
observed under a light microscope at 100X and 400X magnification. We 
observed eggs in urine with this method (Fig. 1). We did a hatching test to 
check the viability of eggs and we got miracidium. It was impossible to infect 
the snails to complete the cycle, we didn´t have Bulinus gender in Brazil and 
it was not recommended to bring them from endemic areas. 
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After the positive diagnosis, with eggs of Schistosoma haematobium 
in urine parasitological examination, the patient received a single oral 
dose of 40 mg praziquantel/kg body weight in 2000, July. Three 24-h 
urine samples collected at intervals of seven days were analyzed by 
the same technique as described above within a minimum period of 21 
days after treatment. Treatment was repeated under medical supervision 
to ensure the correct use of the drug in 2000, October. In view of the 
suspicion of lesions, the patient was submitted to cystoscopy, followed 
by biopsy of observed granulomas and histopathological analysis at six 
month intervals under the same conditions as used during the initial 
diagnosis. The first histopathological exam was performed two months 
(2000, October) after the first treatment (2000, July). Because of a 
suspicion of bladder involvement, a bladder biopsy was performed and 
two fragments were removed, immersed in 10% formalin (one part of 
40% formalin and nine parts of water) and sent to the Laboratory of 
Anatomopathology for the preparation of slides for diagnostic purposes. 
The slides were stained using the following techniques for evaluation 
of treatment: hematoxylin-eosin (Laboratory of Anatomopathology, 
Army Central Hospital, Rio de Janeiro, and Department of Pathology, 
Fiocruz, Rio de Janeiro), Sirius red, pH 10.2, Alcian blue, pH 1.0 and 
2.5, Picrosirius, Masson’s Trichrome, Gomori’s Reticulin, periodic-acid 
Schiff, Ziehl-Neelsen, and Lennert’s Giemsa (Department of Pathology, 
Fiocruz, Rio de Janeiro).
RESULTS
The first histopathological exam performed two months (2000, 
October) after the first treatment (2000, July) revealed edema and 
chronic inflammation of the chorion, presence of chronic granulomatous 
inflammatory process with macrophages and mastocytes, giant cells 
in vesical mucosa, eosinophils, epitheliod cells, multinucleated cell 
granulomas surrounding large amount of viable eggs (Fig. 2). The patient 
received a booster treatment (2000, October) immediately after the result 
of this exam, i.e., two months after the first treatment, under medical 
supervision. Although there was no suspicion of inadequate use of the 
medication, all subsequent treatments were performed under medical 
supervision to ensure the quality of the data. They were done due positive 
results in biopsy of bladder, with granulomas and viable eggs. 
The second histopathological exam (2002, July) performed 23 months 
after the first treatment and 21 months after the second treatment (Fig. 
3 and 4) demonstrated exudative, exudative-produtive and involutional 
phases in granulomas and viable eggs with internal structures (nervous 
system cells, germinative cells). The third treatment was administered 
about 23 months (2002, July) after the first treatment. 
The third histopathological exam (2004, November) performed 51 
months after the first treatment, 49 months after the second treatment and 21 
months after the third treatment (Fig. 5 and 6) revealed granulomas, viable 
eggs with internal structures (nervous system cells, germinative cells, cells 
with pycnotic nuclei around the nervous system) and Langhans cells. 
In view of the repeatedly positive exams and the repetition of 
Fig. 1 - Schistosoma haematobium egg in urine examination (400x magnification). Viable egg 
(white arrow) with miracidium maintaining the internal structures (red arrows). Fig. 2 - Examination after the first treatment (hematoxylin-eosin 40x magnification ). Edema 
and chronic inflammation of the chorion (red arrow), presence of chronic granulomatous 
inflammatory process with macrophages and mastocytes, giant cells in vesical mucosa, 
eosinophils, epitheliod cells, multinucleated cell granulomas surrounding large amount of 
viable eggs (green arrows).
Fig. 3 - Bladder histopathological examination after the second treatment (hematoxylin-eosin 
40x magnification). Exudative, exudative-productive and involutional phases in granulomas 
(red arrows).
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Fig. 4 - Examination after the second treatment (Sirius red ph 10 310x magnification). Viable 
eggs with internal structures (nervous system cells, germinative cells) - brown arrows.
Fig. 5 - Examination after the third treatment (Masson’s trichrome 40x magnification). 
Granulomas, viable eggs with internal structures (nervous system cells, germinative cells, 
cells with pycnotic nuclei around the nervous system) - blue arrows.
Fig. 6 - Examination after the third treatment (PAS 310x magnification). Granuloma, viable 
egg with internal structures (nervous system cells, germinative cells, cells with pycnotic nuclei 
around the nervous system - red arrow) and Langhans cells (green arrow).
Fig. 7 - Examination after fourth treatment (Hematoxylin- Eosin - 200x Magnification). 
Exudative-productive granuloma macrophagic-type with macrophages encircling eggs (black 
arrows) with viable miracidium maintaining the internal structures (blue arrows).
(two treatments in 2004, April and one treatment in 2004, May). These 
treatments were performed about 52 months after the first treatment. In 
addition, another booster treatment at the same dose was applied about 
60 months (2005, June) after the first treatment.
The fourth histopathological exam (Fig. 7, 8 and 9) performed 62 
months (2005, October) after the first treatment and after seven treatments 
administered over the 62 months of follow-up still demonstrated 
exudative-productive granuloma macrophagic-type with macrophages 
encircling eggs with viable miracidium maintaining the internal structures 
(Fig. 7), mast cells with proteoglycans and viable eggs with miracidium 
(Fig. 8) and exudative-productive granulomas in transitional stage to 
productive, concentric arrangement of reticular fibers (Fig. 9), viable eggs 
with miracidium maintaining the internal structures (Fig. 10). 
Before each cystoscopy, three 24-h urine samples collected at 
intervals of seven days were analyzed by the same technique as described 
conventional treatments without an adequate response, three courses of 
treatment with the same dose but at intervals of 15 days were administered 
Fig. 8 - Examination after fourth treatment. (Alcian blue ph 2.5 - 310x magnification). Mast 
cells with proteoglycans and viable eggs with miracidium (pink arrows). 
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Fig. 9 - Examination after fourth treatment (Gomori’s reticulin - 200x magnification). 
Exudative-productive granulomas in transitional stage to productive, concentric arrangement 
of reticular fibers (red arrows) and eggs (black arrows). 
Fig. 10 - Examination after the fourth treatment (Picrosirius 400x magnification). Viable eggs 
with miracidium maintaining the internal structures (green arrows). 
above. All of them were negative to the eggs of the parasite. 
After seven treatments, we lost the contact with the patient, then it was 
not possible to complete the evaluation and to know the final outcome.
DISCUSSION
The histopathological characteristics observed in biopsies obtained, 
after each treatment, indicated viability of parasite eggs and activity of 
granulomas. Since this case has been well monitored, it may contribute 
to the elucidation of an ongoing discussion regarding the resistance to, 
or therapeutic failure of, praziquantel in schistosomiasis haematobia. In 
this respect, each report irrespective of the number of cases described 
but based on the evidence found should contribute to the investigation 
and development of new drugs for the treatment of this infection. In this 
study, like N’GORAN et al., there were no complete signs of resistance 
to praziquantel5, then we considered therapeutic failure instead of 
resistance, because the parasite was not studied in vitro in resistance 
test. We presented in SILVA (2005)6, some cases with active granulomas 
and viable eggs after two controls, but in this presented case, these 
characteristics remained after seven treatments and four controls. The 
patient described in this study is one of the 26 cases reported in SILVA 
(2005)6. The exposition was ten years before and, the first treatment 
was six years after the exposition. A review of the literature shows that 
there is no feasible therapeutic alternative for the increasing number of 
cases described.
RESUMO
Esquistossomíase hematóbica: seguimento histopatológico 
determinado por cistoscopia em um paciente com falha 
terapêutica ao praziquantel
 A Esquistossomíase Hematóbica ou Esquistossomíase Urinária é 
um dos principais problemas de Saúde Pública na África e no Oriente 
Médio. Uma única dose de praziquantel 40 mg/kg de peso, continua 
sendo o tratamento de escolha para esta infecção. Os objetivos deste 
seguimento foram: avaliar o período pós-tratamento de um paciente 
infectado com Schistosoma haematobium e não submetido à re-exposição 
e, identificar as complicações da doença e/ou falha terapêutica, após o 
tratamento com praziquantel, por análise histopatológica de material 
obtido por biópsia vesical. O tratamento foi repetido sob supervisão 
médica para assegurar o uso correto do medicamento. Na presença de 
lesões suspeitas a cistoscopia, o paciente foi submetido a biópsia vesical. 
As características histopatológicas observadas nos materiais obtidos por 
biópsia, após cada tratamento, indicaram viabilidade de ovos e atividade 
dos granulomas. 
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